Recommendations for management of liver and biliary tract disease in cystic fibrosis

Journal of Pediatric Gastroenterology and Nutrition

Volumn 28, Issue SUPPL. 1, 1999, Pages

  Sokol, Ronald J ^a,b   Durie, Peter R ^c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIFEDIOL; DIGLYCINE TECHNETIUM TC 99M; DIURETIC AGENT; FUROSEMIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; LACTULOSE; MEDIUM CHAIN TRIACYLGLYCEROL; NEOMYCIN; OCTREOTIDE; PROPRANOLOL; RIFAMPICIN; SPIRONOLACTONE; TRANSMEMBRANE CONDUCTANCE REGULATOR; URSODEOXYCHOLIC ACID; VASOPRESSIN; VITAMIN K GROUP;

ADOLESCENT; ADULT; ARTIFICIAL MILK; ASCITES; BILIARY TRACT DISEASE; BLEEDING; BONE MARROW SUPPRESSION; BRONCHOSPASM; CHILD; CHOLELITHIASIS; CHOLESTASIS; CYSTIC FIBROSIS; DIARRHEA; DIET THERAPY; GYNECOMASTIA; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERTENSION; INFANT; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; MAJOR CLINICAL STUDY; METABOLIC DISORDER; NEPHROTOXICITY; PORTAL HYPERTENSION; PRIORITY JOURNAL; PRURITUS; REVIEW;

BILIARY TRACT DISEASES; CYSTIC FIBROSIS; EPITHELIUM; HUMANS; HYPERTENSION, PORTAL; LIVER DISEASES; LIVER FAILURE; NUTRITION PHYSIOLOGY;

EID: 0033044146     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-199900001-00001     Document Type: Review

References (87)

1. Anderson DH. Cystic fibrosis of the pancreas and its relation to cehac disease. Am J Dis Child 1938;56:344-99.
2. Conn JA, Strong TV, Picciotto MR, et al. Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology 1993;105:1857-64.
3. Grubman SA, Fang SL, Mulberg AE, et al. Correction of the cystic fibrosis defect by gene complementation in human intrahepatic biliary epithelial cell lines. Gastroenterology 1995;108:584-92.
4. Colombo C, Apostolo MG, Ferrari M, et al. Analysis of risk factors for the development of liver disease associated with cystic fibrosis. J Pediatr 1994;124:393-9.
5. Duthie A, Doherty DG, Williams C, et al. Genotype analysis for ΔF508, G551D, and R553X mutations in children and young adults with cystic fibrosis with and without chronic liver disease. Hepatology 1992;15:660-4.
6. De Arce M, O'Brien S, Hegarty J, et al. Deletion ΔF508 and clinical expression of cystic fibrosis-related liver disease. Clin Genet 1922;42:271-2.
7. Augarten A, Kerem B-S, Yahav Y, et al. Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849+10 kb C to T mutation. Lancet 1993;342:25-6.
8. Kovesi T, Corey M, Tsui L-C, et al. The association between liver disease and mutations of the cystic fibrosis gene (abstract) Pediatr Pulmonol 1992;(Suppl)8:244.
9. Duthie A, Doherty DG, Donaldson PT, et al. The major histocompatibility complex influences the development of chronic liver disease in male children and young adults with cystic fibrosis. J Hepatol 1995;23:532-7.
10. Rosser BG, Gores GJ. Liver cell necrosis: Cellular mechanisms and clinical implications. Gastroenterology 1995;108:252-75.
11. Lindblad A, Hultcramtz R, Strandvik B. Bile-duct destruction and collagen deposition: A prominent ultrastructural feature of the liver in cystic fibrosis. Hepatology 1992;16:372-81.
12. Malizia G, Brunt EM, Peters MG, et al. Growth factor and procollagen type 1 gene expression in human liver disease. Gastroenterology 1995;108:145-56.
13. Sinaasappel M. Hepatobiliary pathology in patients with cystic fibrosis. Acta Paediatr Scand Suppl 1989;363:45-51.
14. Kuroki T, Seki S, Kawakita N, et al. Expression of antigens related to apoptosis and cell proliferation in chronic nonsuppurative destructive cholangitis in primary biliary cirrhosis. Virchows Arch 1996;429:119-29.
15. Gaskin KJ, Waters DLM, Howman-Giles R, et al. Liver disease and common-bile-duct stenosis in cystic fibrosis. N Engl J Med 1988;318:340-6.
16. Nagel RA, Javaid A, Meire HB, et al. Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet 1989;2:1422-5.
17. O'Brien S, Keogan M, Casey M, et al. Biliary complications of cystic fibrosis. Gut 1992;33:387-91.
18. Lykavieris P, Bernard O, Hadchouel M. Neonatal cholestasis as the presenting feature in cystic fibrosis. Arch Dis Child 1996;75:67-70.
19. Wilroy RS, Crawford SE, Johnson WW. Cystic fibrosis with extensive fat replacement of the liver. J Pediatr 1966;68:67-73.
20. Strandvik B, Lultcramtz R: Liver function and morphology during long-term fatty acid supplementation in cystic fibrosis Liver 1994; 14:32-6.
21. Treem WR, Stanley CA. Massive hepatomegaly, steatosis and secondary plasma carnitine deficiency in an infant with cystic fibrosis. Pediatrics 1989;83:993-7.
22. Feingold KR, Serio MK, Adi S, Moser AH, Grunfeld C. Tumor necrosis factor stimulates hepatic lipid synthesis and secretion. Endocrinology 1989;124:2336-42.
23. Bacon BR, Farahvash MJ, Janney CG, Neushwander-Tetri BA. Nonalcoholic steatohepatitis: An expanded clinical entity. Gastroenterology 1994;107:1103-9.
24. Linugasa A, Tsunamoto K, Furukawa N, Sawada T, Kusunoki T, Shimada N. Fatty liver and its fibrous changes found in simple obesity of children. J Pediatr Gastroenterol Nutr 1984;3:408-14.
25. Tizzano EF, Chitayat D, Buchwald M. Cell-specific localization of CFTR mRNA shows developmentally regulated expression in human fetal tissues. Hum Mol Genet 1993;2;219-24.
26. FitzSimmons SC. Cystic Fibrosis Foundation Patient Registry. Annual Data Base Report. Bethesda, Maryland, August, 1997.
27. Feigelson J, Anagnostopoulos C, Poquet M, Pecau Y, Munck A, Navarro J. Liver cirrhosis in cystic fibrosis: Therapeutic implications and long term follow up. Arch Dis Child 1993;68:653-7.
28. Scott-Jupp R, Lama M, Tanner MS. Prevalence of liver disease in cystic fibrosis. Arch Dis Child 1991;66:698-701.
29. Sokol RJ, Carroll NM, Narkewicz MR, Wagener JS, Accurso FJ. Liver blood tests during the first decade of life in children with cystic fibrosis identified by newborn screening (abstract). Pediatr Pulmonol 1994;10(Suppl):275.
30. Kovesi T, Corey M, Tsui L-C, Levison H, Durie P. The association between liver disease and mutations of the cystic fibrosis gene (abstract). Pediatr Pulmonol 1992;8(Suppl):244.
31. Shwachman H, Kowalski M, Khaw KT. Cystic fibrosis: A new outlook; 70 patients above 25 years of age. Medicine 1977;56:129-49.
32. Oppenheimer EH, Esterly JR. Hepatic changes in young infants with cystic fibrosis: Possible relation to focal biliary cirrhosis. J Pediatr 1975;86:683-9.
33. Vawter GF, Shwachman H. Cystic fibrosis in adults: An autopsy study. Pathol Ann 1979;14:357-82.
34. Lykavieris P, Obernard O, Hadchouel M. Neonatal cholestasis as the presenting feature in cystic fibrosis. Arch Dis Child 1996;75: 67-70.
35. Willi UV, Reddish JM, Littlewood Teele R. Cystic fibrosis: Its characteristic appearance on abdominal sonography. Am J Radiol 1980;134:1005-10.
36. Neglia JP, FitzSimmons SC, Maisonneuve P, et al. The risk of cancer among patients with cystic fibrosis. Cystic fibrosis and cancer study group. N Engl J Med 1995;332:494-9.
37. Sokol RJ. Fat-soluble vitamins and their importance in patients who have cholestatic liver disease. Gastroenterol Clin North Am 1994;23:673-705.
38. Maurage C. Lenaerts C, Weber A, Brochu P, Yousef I, Roy CC. Meconium ileus and its equivalent as a risk factor the development of cirrhosis: An autopsy study in cystic fibrosis. J Pediatr Gastroenterol Nutr 1989;9:17-20.
39. Lawson EE, Grand RJ, Neff RK, Cohen L. Clinical estimation of liver span in infants and children. Am J Dis Child 1978;132:474-6.
40. Bern E, Oates E, Setchell K, Terrin M, FitzSimmons S, O'Connell N, Grand RJ, and the CF Collaborative Liver Disease Study Group. Comparison of hepatobiliary scintigraphy and other markers in cystic fibrosis associated liver disease. Submitted for publication.
41. Schoenau E, Boeswald W, Wanner R, et al. High molecular mass ("biliary") isoenzyme of alkaline phosphatase in the diagnosis of liver dysfunction in cystic fibrosis. Clin Chem 1989;35:1888-90.
42. Rattenbury JM, Taylor CJ, Heath PK, Howie AF, Beckett GJ. Serum glutathione S-transferase B1 activity as an index of liver function in cystic fibrosis. J Clin Pathol 1995;48:771-4.
43. Gerling B, Becker M, Staab D, Schuppan D. Prediction of liver fibrosis according to serum collagen VI level in children with cystic fibrosis. N Engl J Med 1997;336:1611-2.
44. Valletta EA, Loreti S, Cipolli M, Cazzola G, Zanolla L. Portal hypertension and esophageal varices in cystic fibrosis. Unreliability of echo-Doppler flowmetry. Scand J Gastroenterol 1993;28: 1042-6.
45. Heyman S. Hepatobiliary scintigraphy as a liver function test. J Nucl Med 1994;35:436-47.
46. Dogan AS, Conway JJ, Lloyd-Still JD. Hepatobiliary scintigraphy in children with cystic fibrosis and liver disease. J Nucl Med 1994; 35:432-5.
47. O'Connor PJ, Southern KW, Bowler IM, et al. The role of hepatobiliary scintigraphy in cystic fibrosis. Hepatology 1996;23: 281-7.
48. Colombo C, Castellani MR, Balistreri WF, et al. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology 1992;15: 677-84.
49. Price MR, Sartorelli KH, Karrer FM, Narkewicz MR, Sokol RJ, Lilly JR. Management of esophageal varices in children by endoscopic variceal ligation. J Pediatr Surg 1996;31:1056-9.
50. Hayes PC, Davis JM, Lewis JA, Boucher IAD. Meta-analysis of value of propranolol in prevention of variceal hemorrhage. Lancet 1990;336:153-6.
51. Teran JC, Imperiale TF, Mullen KD, Tavill AS, McCullough. Primary prophylaxis of variceal bleeding in cirrhosis: A cost-effectiveness analysis. Gastroenterology 1997;112:473-82.
52. Grace ND. Prevention of initial variceal hemorrhage. Gastroenterol Clin North Am 1992;21:149-61.
53. Hubbard AM, Meyer JS, Mahboubi S. Diagnosis of liver disease in children: Value of MR angiography. AJR Am J Roentgenol 1992; 159:617-21.
54. Naveh Y, Berant M. Assessment of liver size in normal infants and children. J Pediatr Gastroenterol Nutr 1984;3:346-8.
55. Potter CJ, Fishbein M, Hammond S, McCoy K, Qualman S. Can the histologic changes of cystic fibrosis-associated hepatobiliary disease be predicted by clinical criteria? J Pediatr Gastroenterol Nutr 1997;25:32-6.
56. Otani YS, Ziegler JW, Sokol RJ, Horgan JG, Sondheimer HM, Narkewicz MR. Hepatic function after the Fontan procedure (abstract). J Pediatr Gastroenterol Nutr 1996;23:351
57. Sokol RJ, Reardon MC, Accurso FJ, Stall C, Narkewicz MR, Abman SH, Hammond KD. Fat soluble vitamins in infants identified by cystic fibrosis newborn screening. Pediatr Pulmonol 1991; (Suppl)7:52-5.
58. LePage G, Champagne J, Ronco N, et al. Supplementation with carotenoids corrects lipid peroxidation in children with cystic fibrosis. Am J Clin Nutr 1996;64:87-93.
59. Heuman DM. Hepatoprotective properties of ursodeoxycholic acid. Gastroenterology. 1993;104:1865-70.
60. Hofmann AF. Bile acid hepatotoxicity and the rationale for UDCA therapy in chronic cholestatic liver diseases: Some hypotheses. In: Paumgartner G, Stiehl A, Barbara L, Roda E, eds. Strategies for the treatment of hepatobiliary diseases. Dordrecht: Kluwer Academic, 1990:13-33.
61. Botla R, Spivey JR, Aguilar H, Bronk SF, Gores GJ. Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: A mechanism of UDCA cytoprotection. J Pharmacol Exp Ther 1995;272:930-8.
62. Galabert C, Montet JC, Lengrand D, et al. Effects of ursodeoxycholic acid on liver function in patients with cystic fibrosis and chronic cholestasis. J Pediatr 1992;121:138-41.
63. Colombo C, Battezzati PM, Podda M, et al. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: A double-blind multicenter trial. Hepatology 1996;23:1484-90.
64. Strandvik B, Lindblad A. Cystic fibrosis: Is treatment with ursodeoxycholic acid of value? Scand J Gastroenterol 1994;29(Suppl): 65-7.
65. Colombo C, et al. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: A dose-response study. Hepatology 1992; 16:924-30.
66. Narkewicz MR, Smith D, Gregory C, Lear J, Osberg I, Sokol RJ. Effect of ursodeoxycholic acid therapy on hepatic function in children with intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 1998:26:49-55.
67. Lepage G, Paradis K, Lacaille F, et al. Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis. J Pediatr 1997;130:52-8.
68. Cotting J, Lentze MJ, Reichen J. Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis. Gut 1990;31:918-21.
69. Merli M, Bertasi S, Servi R, et al. Effect of a medium dose of ursodeoxycholic acid with or without taurine supplementation on the nutritional status of patients with cystic fibrosis: A randomized, placebo-controlled, crossover trial. J Pediatr Gastroenterol Nutr 1994;19:98-203.
70. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113:884-90.
71. Setchell KDR, O'Connell NC, Bern E, et al. Markedly decreased ursodeoxycholic acid (UDCA) enrichment with high dose UDCA in cystic fibrosis (CF) associated liver disease: Optimization of the therapeutic dose (abstract). Hepatology 1994;20:262A.
72. Colombo C, Bertolini E, Assaisso ML, Bettinardi N, Giunta A, Podda M. Failure of ursodeoxycholic acid to dissolve radiolucent gallstones in patients with cystic fibrosis. Acta Paediatr 1993;82: 562-5.
73. Ramsey BW, Farrell P, Pencharz PB. Nutritional assessment and management in cystic fibrosis: A consensus report. Am J Clin Nutr 1992;55:108-16.
74. Pierro A, Koletzko B, Carnelli V, et al. Resting enery expenditure is increased in infants and children with extrahepatic biliary atresia. J Pediatr Surg 1989;24:534-8.
75. Goff JS. Esophageal varices. Gastrointest Endosc Clin North Am 1994;4:747-71.
76. Rossle M, Haag K, Ochs A, Sellinger M, Noldge G, Perarnau J-M, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med 1994;330:165-71.
77. Stern RC, Stevens DP, Boat TF, Doershuk CF, Izant RRJ Jr., Matthews LW. Symptomatic hepatic disease in cystic fibrosis. incidence, course, and outcome of portal systemic shunting Gastroenterology 1976;70:645-9.
78. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995;333:984-91.
79. Ozsoylu S, Kocak N, Yuce A. Propranolol therapy for portal hypertension in children. J Pediatr 1985;106:317-21.
80. Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: A meta-analysis. Hepatology 1997; 25:63-70.
81. Hardy SC, Kleinman RE. Cirrhosis and chronic liver failure. In: Suchy FJ, ed. Liver disease in children. St. Louis: Mosby, 1994: 214-48.
82. Mack DR, Traystman MD, Colombo JL, et al. Clinical denouement and mutation analysis of patients with cystic fibrosis undergoing liver transplantation for biliary cirrhosis. J Pediatr 1995;127: 881-7.
83. Noble-Jamieson G, Valente J, Barnes ND, et al. Liver transplantation for hepatic cirrhosis in cystic fibrosis. Arch Dis Child 1994; 71:349-52.
84. Yang Y, Draper SE, Cohn JA, Engelhardt JF, Wilson JM. An approach for treating the hepatobiliary disease of cystic fibrosis somatic gene transfer. Proc Natl Acad Sci USA 1993;90:4601-05.
85. Friedman SL. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993;328:1828-35.
86. Britton RS, Bacon BR. Role of free radicals in liver diseases and hepatic fibrosis. Hepato-Gastroenterology 1994;41:343-8.
87. Zhang M, Song G, Minuk GY. Effects of hepatic stimulator substance, herbal medicine, selenium/vitamin E, and ciprofloxacin on cirrhosis in the rat. Gastroenterology 1996;110:1150-5.